Patents by Inventor Sangeeta Ray

Sangeeta Ray has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PSMA TARGETED RADIOHALOGENATED UREAS FOR CANCER RADIOTHERAPY
    Publication number: 20240140971
    Abstract: PSMA binding scaffolds with radioiodinated, radiobrominated and radioastatinated labeled prosthetic groups are disclosed. Pharmaceutical compositions and methods of treating PSMA expressing cells or tumors also are disclosed.
    Type: Application
    Filed: June 14, 2023
    Publication date: May 2, 2024
    Inventors: Martin G. Pomper, Ronnie C. Mease, Ying Chen, Sangeeta Ray, Michael Zalutsky, Ganesan Vaidyanathan
  • Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy
    Patent number: 11911488
    Abstract: Carbamate and beta-amino acid urea-based scaffolds that have high binding affinity to PSMA are disclosed. These scaffolds can be radiolabeled and used for imaging cells and tumors that express PSMA or for cancer radiotherapy. These compounds also can comprise a fluorescent dye and be used for imaging cells and tumors that express PSMA or for photodynamic therapy.
    Type: Grant
    Filed: August 4, 2020
    Date of Patent: February 27, 2024
    Assignee: THE JOHNS HOPKINS UNIVERSTY
    Inventors: Martin G. Pomper, Ronnie C. Mease, Sangeeta Ray, Ying Chen, Xing Yang
  • Raman spectroscopy reporters and methods for molecular imaging of tissue in vivo
    Patent number: 11871895
    Abstract: The present invention provides a targeted nanoplex platform for in vivo imaging and theranostic imaging of cancer to simultaneously provide non-invasive assessment of tumor burden and cancer-selective treatments.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: January 16, 2024
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Ming Li, Ishan Barman, Martin Pomper, Sangeeta Ray
  • PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy
    Patent number: 11813340
    Abstract: Small molecule radiohalogenated PSMA inhibitors and metal complexes thereof and their use in radioimaging and radiotherapy for treating PSMA-related diseases, including prostate cancer, are disclosed. The combination of small molecule radiohalogenated PSMA inhibitors with a competitive PSMA ligand for reducing off target accumulation of the radiohalogenated PSMA inhibitor also is disclosed.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: November 14, 2023
    Assignees: The Johns Hopkins University, Duke University
    Inventors: Martin G. Pomper, Ronnie C. Mease, Vivek Kumar, Sangeeta Ray, Michael Zalutsky, Ganesan Vaidyanathan
  • PSMA targeted fluorescent agents for image guided surgery
    Patent number: 11814365
    Abstract: Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: November 14, 2023
    Assignee: The Johns Hopkins University
    Inventors: Martin G. Pomper, Ronnie C. Mease, Ying Chen, Sangeeta Ray
  • PSMA-TARGETING COMPOUNDS AND USES THEREOF
    Publication number: 20230348405
    Abstract: Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
    Type: Application
    Filed: November 4, 2022
    Publication date: November 2, 2023
    Inventors: Martin G. Pomper, Ronnie C. Mease, Ying Chen, Sangeeta Ray
  • PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USES THEREOF
    Publication number: 20230226227
    Abstract: The present disclosure relates to prostate specific membrane antigen (PSMA) ligands. In particular, the disclosure relates to PSMA ligands having a glutamate-urea-lysine (GUL) moiety and a chelating agent that can comprise a radiometal. The disclosure also relates to the use of these compounds in imaging and in the treatment of prostate cancer.
    Type: Application
    Filed: June 30, 2020
    Publication date: July 20, 2023
    Inventors: Maurizio F. MARIANI, Lorenza FUGAZZA, Daniela CHICCO, Martin Gilbert POMPER, Sangeeta RAY
  • PSMA-targeting compounds and uses thereof
    Patent number: 11661402
    Abstract: Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
    Type: Grant
    Filed: April 12, 2022
    Date of Patent: May 30, 2023
    Assignee: The Johns Hopkins University
    Inventors: Martin G. Pomper, Ronnie C. Mease, Ying Chen, Sangeeta Ray
  • PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETED HIGH-AFFINITY AGENTS FOR ENDORADIOTHERAPY OF PROSTATE CANCER
    Publication number: 20230147035
    Abstract: Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer are disclosed.
    Type: Application
    Filed: October 24, 2022
    Publication date: May 11, 2023
    Inventors: Sangeeta Ray, Martin G. Pomper
  • PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETED HIGH-AFFINITY AGENTS FOR ENDORADIOTHERAPY OF PROSTATE CANCER
    Publication number: 20230015736
    Abstract: Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer are disclosed.
    Type: Application
    Filed: August 22, 2022
    Publication date: January 19, 2023
    Inventors: SANGEETA RAY, MARTIN G. POMPER
  • Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
    Patent number: 11478558
    Abstract: Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer are disclosed.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: October 25, 2022
    Assignee: The Johns Hopkins University
    Inventors: Sangeeta Ray, Martin G. Pomper
  • Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
    Patent number: 11458213
    Abstract: Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer are disclosed.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: October 4, 2022
    Inventors: Sangeeta Ray, Martin G. Pomper
  • PSMA-TARGETING COMPOUNDS AND USES THEREOF
    Publication number: 20220259161
    Abstract: Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
    Type: Application
    Filed: April 12, 2022
    Publication date: August 18, 2022
    Inventors: Martin G. Pomper, Ronnie C. Mease, Ying Chen, Sangeeta Ray
  • METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY
    Publication number: 20220135529
    Abstract: Low-molecular weight gadolinium (Gd)-based MR contrast agents for PSMA-specific T1-weighted MR imaging are disclosed. The (Gd)-based MR contrast agents exhibit high binding affinity for PSMA and exhibit specific T1 contrast enhancement at PSMA+ cells. The PSMA-targeted Gd-based MR contrast agents can be used for PSMA-targeted imaging in vivo. 86Y-labeled PSMA-binding ureas also are provided, wherein the PSMA-binding ureas also are suitable for use with other radiotherapeutics.
    Type: Application
    Filed: January 13, 2022
    Publication date: May 5, 2022
    Inventors: Sangeeta Ray, Martin G. Pomper, Thomas J. Meade, Ronnie C. Mease, Ying Chen, Xing Yang, Matthew Rotz
  • PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERY
    Publication number: 20220048872
    Abstract: Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
    Type: Application
    Filed: May 26, 2021
    Publication date: February 17, 2022
    Inventors: Martin G. Pomper, Ronnie C. Mease, Ying Chen, Sangeeta Ray
  • COMPETITIVE PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) BINDING AGENTS FOR REDUCTION OF NON-TARGET ORGAN UPTAKE OF RADIOLABELED PSMA INHIBITORS FOR PSMA POSITIVE TUMOR IMAGING AND RADIOPHARMACEUTICAL THERAPY
    Publication number: 20210338846
    Abstract: Methods for co-injection of a non-radioactive PSMA inhibitor, referred to herein as a competing inhibitor (CI), with a radiolabeled PSMA inhibitor are disclosed. This combination reduces the uptake of the radiotracer in non-target organs, including the kidneys and lacrimal glands, with only a modest reduction in tumor uptake.
    Type: Application
    Filed: July 30, 2019
    Publication date: November 4, 2021
    Inventors: Martin G. Pomper, Ronnie C. Mease, Sangeeta Ray, IL Minn
  • LONG-CIRCULATING PSMA-TARGETED PHOTOTHERANOSTIC AGENT
    Publication number: 20210308286
    Abstract: Theranostic probes comprising a porphyrin-based photosensitizer, a D-peptide linker, and a urea-based PSMA-targeting ligand and methods of their use for treating and/or imaging PMSA-expressing tumors are disclosed.
    Type: Application
    Filed: July 30, 2019
    Publication date: October 7, 2021
    Inventors: Martin G. Pomper, Ronnie C. Mease, Ying Chen, Sangeeta Ray, Juan Chen, Marta Overchuk, Kara Harmatys, Gang Zheng
  • Triazole conjugated ureas, thioureas, carbamates, and reversed carbamates for PSMA-targeted imaging agents and uses thereof
    Patent number: 11078166
    Abstract: Triazole conjugated urea-based and thiourea-based scaffolds that have high binding affinity to PSMA are disclosed. These scaffolds can be radiolabeled and used to image cells and tumors that express PSMA. Methods of synthesizing radiofluorinated triazole conjugated urea-based and thiourea-based scaffolds also are disclosed.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: August 3, 2021
    Assignee: The Johns Hopkins University
    Inventors: Martin G. Pomper, Ying Chen, Xing Yang, Ronnie C. Mease, Sangeeta Ray
  • PSMA TARGETED RADIOHALOGENATED UREA-POLYAMINOCARBOXYLATES FOR CANCER RADIOTHERAPY
    Publication number: 20210220493
    Abstract: Small molecule radiohalogenated PSMA inhibitors and metal complexes thereof and their use in radioimaging and radiotherapy for treating PSMA-related diseases, including prostate cancer, are disclosed. The combination of small molecule radiohalogenated PSMA inhibitors with a competitive PSMA ligand for reducing off target accumulation of the radiohalogenated PSMA inhibitor also is disclosed.
    Type: Application
    Filed: February 6, 2019
    Publication date: July 22, 2021
    Inventors: Martin G. Pomper, Ronnie C. Mease, Vivek Kumar, Sangeeta Ray, Michael Zalutsky, Ganesan Vaidyanathan
  • PSMA targeted fluorescent agents for image guided surgery
    Patent number: 11021450
    Abstract: Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: June 1, 2021
    Assignee: The Johns Hopkins University
    Inventors: Martin G. Pomper, Ronnie C. Mease, Ying Chen, Sangeeta Ray